acetylcarnitine has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS)." | 5.17 | Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. ( Beghi, E; Bella, VL; Bonito, V; Buzzi, P; Caponnetto, C; Chiò, A; Corbo, M; Giannini, F; Inghilleri, M; Logroscino, G; Lorusso, L; Lunetta, C; Mazzini, L; Messina, P; Mora, G; Perini, M; Pupillo, E; Quadrelli, ML; Silani, V; Simone, IL; Tremolizzo, L, 2013) |
| " The effect was due to a shift to the right of the dose-response curve for kainate (EC50 for kainate 5." | 1.31 | Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. ( Bigini, P; Larini, S; Mennini, T; Muzio, V; Pasquali, C, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sassi, S | 1 |
| Bianchi, E | 1 |
| Diamanti, L | 1 |
| Tornabene, D | 1 |
| Sette, E | 1 |
| Medici, D | 1 |
| Matà, S | 1 |
| Leccese, D | 1 |
| Sperti, M | 1 |
| Martinelli, I | 1 |
| Ghezzi, A | 1 |
| Mandrioli, J | 1 |
| Iuzzolino, VV | 1 |
| Dubbioso, R | 1 |
| Trojsi, F | 1 |
| Passaniti, C | 1 |
| D'Alvano, G | 1 |
| Filosto, M | 1 |
| Padovani, A | 1 |
| Mazzini, L | 2 |
| De Marchi, F | 1 |
| Zinno, L | 1 |
| Nuredini, A | 1 |
| Bongioanni, P | 1 |
| Dolciotti, C | 1 |
| Canali, E | 1 |
| Toschi, G | 1 |
| Petrucci, A | 1 |
| Perna, A | 1 |
| Riso, V | 1 |
| Inghilleri, M | 2 |
| Libonati, L | 1 |
| Cambieri, C | 1 |
| Pupillo, E | 2 |
| Gibbs, KL | 1 |
| Kalmar, B | 1 |
| Rhymes, ER | 1 |
| Fellows, AD | 1 |
| Ahmed, M | 1 |
| Whiting, P | 1 |
| Davies, CH | 1 |
| Greensmith, L | 1 |
| Schiavo, G | 1 |
| Beghi, E | 1 |
| Bonito, V | 1 |
| Buzzi, P | 1 |
| Caponnetto, C | 1 |
| Chiò, A | 1 |
| Corbo, M | 1 |
| Giannini, F | 1 |
| Bella, VL | 1 |
| Logroscino, G | 1 |
| Lorusso, L | 1 |
| Lunetta, C | 1 |
| Messina, P | 1 |
| Mora, G | 1 |
| Perini, M | 1 |
| Quadrelli, ML | 1 |
| Silani, V | 1 |
| Simone, IL | 1 |
| Tremolizzo, L | 1 |
| Bigini, P | 1 |
| Larini, S | 1 |
| Pasquali, C | 1 |
| Muzio, V | 1 |
| Mennini, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Patient Centric Motor Neuron Disease Activities of Daily Living Scale[NCT02852278] | 410 participants (Actual) | Observational | 2016-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for acetylcarnitine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.
Topics: Acetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Metho | 2013 |
3 other studies available for acetylcarnitine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Retrospective observational study on the use of acetyl-L-carnitine in ALS.
Topics: Acetylcarnitine; Amyotrophic Lateral Sclerosis; Case-Control Studies; Double-Blind Method; Humans; R | 2023 |
Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS.
Topics: Acetylcarnitine; Amyotrophic Lateral Sclerosis; Animals; Axonal Transport; Disease Models, Animal; E | 2018 |
Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons.
Topics: Acetylcarnitine; Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Choline O-Acetyltransferas | 2002 |